Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
7.56
USD
|
+0.80%
|
|
-27.59%
|
+85.29%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,833
|
750.2
|
804.3
|
1,675
|
-
|
-
|
Enterprise Value (EV)
1 |
2,691
|
750.2
|
703.2
|
1,344
|
1,311
|
1,366
|
P/E ratio
|
-7.23
x
|
-2.76
x
|
-2.79
x
|
-6.3
x
|
-6.74
x
|
-5.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-7.78
x
|
-2.92
x
|
-2.62
x
|
-5.66
x
|
-6.06
x
|
-2.26
x
|
EV / FCF
|
-9.58
x
|
-
|
-2.57
x
|
-6.19
x
|
-6.55
x
|
-6.07
x
|
FCF Yield
|
-10.4%
|
-
|
-38.9%
|
-16.1%
|
-15.3%
|
-16.5%
|
Price to Book
|
4.03
x
|
-
|
2.81
x
|
3.47
x
|
3.67
x
|
-
|
Nbr of stocks (in thousands)
|
183,042
|
189,920
|
197,132
|
221,503
|
-
|
-
|
Reference price
2 |
15.48
|
3.950
|
4.080
|
7.560
|
7.560
|
7.560
|
Announcement Date
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-280.2
|
-345.8
|
-256.9
|
-268.6
|
-237.6
|
-216.4
|
-605.8
|
EBIT
1 |
-
|
-286.1
|
-356.9
|
-272.6
|
-293.1
|
-307.5
|
-291.2
|
-449.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-264.6
|
-281.3
|
-443.4
|
Net income
1 |
-130.8
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-266.2
|
-277.2
|
-430.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-6.670
|
-21.92
|
-2.140
|
-1.430
|
-1.460
|
-1.199
|
-1.122
|
-1.468
|
Free Cash Flow
1 |
-
|
-161.9
|
-280.9
|
-
|
-273.6
|
-217
|
-200
|
-225
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/20
|
3/24/21
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-28.07
|
-69.1
|
-82.17
|
-
|
-79.71
|
-111.8
|
-
|
-79.36
|
-
|
-43.08
|
-37.96
|
-
|
-
|
-
|
EBIT
1 |
-111.3
|
-31.68
|
-72.9
|
-86.19
|
-81.79
|
-84.05
|
-116.3
|
-2.181
|
-90.62
|
-110.7
|
-66.06
|
-62.99
|
-61.42
|
-77.05
|
-85.69
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-107.5
|
-66.92
|
-67.21
|
-67.85
|
-77.05
|
-85.69
|
Net income
1 |
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-107.5
|
-65.64
|
-66.07
|
-66.52
|
-77.05
|
-85.69
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.1700
|
-0.3900
|
-0.4500
|
-0.4200
|
-0.4300
|
-0.5900
|
-
|
-0.4500
|
-0.4900
|
-0.2780
|
-0.2660
|
-0.2660
|
-0.3300
|
-0.3700
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/22
|
5/10/22
|
8/4/22
|
11/2/22
|
3/16/23
|
5/8/23
|
8/3/23
|
11/8/23
|
2/29/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
52.9
|
142
|
-
|
101
|
331
|
364
|
308
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-162
|
-281
|
-
|
-274
|
-217
|
-200
|
-225
|
ROE (net income / shareholders' equity)
|
-
|
-80.8%
|
-194%
|
-
|
-72%
|
-75.7%
|
-60.4%
|
-64.3%
|
ROA (Net income/ Total Assets)
|
-
|
-49.8%
|
-32.1%
|
-
|
-40.8%
|
-42%
|
-41.4%
|
-38%
|
Assets
1 |
-
|
572.8
|
1,110
|
-
|
694
|
633.6
|
670
|
1,135
|
Book Value Per Share
2 |
-
|
-
|
3.840
|
-
|
1.450
|
2.180
|
2.060
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
23.9
|
29.9
|
-
|
20
|
18
|
12.5
|
13
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/20
|
3/24/21
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
7.56
USD Average target price
11.5
USD Spread / Average Target +52.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +85.29% | 1.67B | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|